Bayesian Indirect Comparison and Cost-Effectiveness of Sacituzumab Govitecan Versus Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer - PubMed
7 hours ago
- #cost-effectiveness
- #mTNBC
- #Bayesian
- Bayesian indirect comparison and cost-effectiveness analysis of Sacituzumab Govitecan (SG) vs. Sacituzumab Tirumotecan (sac-TMT) in metastatic triple-negative breast cancer (mTNBC).
- SG showed slightly better health outcomes (0.095 additional QALYs) but at a significantly higher cost ($68,266 incremental cost).
- Incremental cost-effectiveness ratio (ICER) for SG vs. sac-TMT was $719,726 per QALY, making SG not cost-effective at current prices.
- Sensitivity analyses identified SG price and model time horizon as key factors affecting cost-effectiveness.
- Probabilistic results showed 0% likelihood of SG being cost-effective at a willingness-to-pay threshold of $40,763 per QALY.
- Indirect comparisons and economic modeling can guide payer decisions and pricing negotiations in the absence of head-to-head data.